Moderna faces declining demand for COVID vaccine, but aims for future growth with new products.

Moderna, once a stock market star, has faced declining demand for its coronavirus vaccine, resulting in declining sales and stock performance. However, the company is gearing up for potential growth with several product launches on the horizon. With shares down more than 90% since their peak in 2021, investors may see an opportunity to add Moderna to their portfolio at a lower price. The company aims to launch as many as 10 new products in the next three years, potentially leading to significant revenue growth in the future. Despite recent struggles, Moderna’s long-term prospects are hopeful.

Looking ahead, Moderna expects to have about 10 products on the market in 10 years, including cancer vaccines and respiratory virus vaccines. The company’s strong success rate in late-stage trials bodes well for its future product launches. By 2028, Moderna predicts breaking even on an operating cash cost basis and generating $6 billion in revenue. New product launches from 2026 to 2028 could result in a compounded annual growth rate of 25% or more. While Moderna stock may be facing challenges now, the company’s future growth potential is promising.

The Motley Fool Stock Advisor analyst team has identified what they believe are the 10 best stocks to buy now, and Moderna wasn’t one of them. Investors considering Moderna should weigh the company’s long-term growth prospects against current challenges. Joining the Stock Advisor platform could provide insights into potential investment opportunities with high return potential.

Read more at Nasdaq: Where Will Moderna Be in 10 Years?